Certolizumab Pegol

Summary

Certolizumab Pegol (CHEMBL1201831) is an approved antibody (ATC L04AB05); indicated across 11 conditions including rheumatoid arthritis and psoriatic arthritis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Antibody
• ATC class: L04AB05
• Indications: 11 conditions
• Clinical trials: 90

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201831
Name	Certolizumab Pegol
Type	Antibody
Max phase	4
ATC	L04AB05

Also known as: CDP 870, CDP-870, CDP870, Certolizumab pegol, Cimzia, PHA-738144, CERTOLIZUMAB PEGOL

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

11 indications (6 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
rheumatoid arthritis	4	MONDO:0008383	EFO:0000685
psoriatic arthritis	4	MONDO:0011849	EFO:0003778
ankylosing spondylitis	4	MONDO:0005306	EFO:0003898
Crohn disease	4	MONDO:0005011	EFO:0000384
immune system disorder	4	MONDO:0005046	EFO:0000540
juvenile idiopathic arthritis	3	MONDO:0011429	EFO:0002609
psoriasis	3	MONDO:0005083	EFO:0000676
interstitial cystitis	3	MONDO:0018301	EFO:1000869
ulcerative colitis	2	MONDO:0005101	EFO:0000729

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 90.

Phase distribution

Phase	Trials
PHASE3	47
PHASE4	14
PHASE2	10
Not specified	10
PHASE1	7
PHASE2/PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00580840	PHASE4	COMPLETED	Dosing Flexibility Study in Patients With Rheumatoid Arthritis
NCT00993668	PHASE4	COMPLETED	Assessing the Use of Certolizumab Pegol in Adult Subjects With Rheumatoid Arthritis on the Antibody Response When Receiving Influenza Virus and Pneumococcal Vaccines
NCT01024647	PHASE4	UNKNOWN	Optimizing Cimzia in Crohn’s Patients
NCT01147341	PHASE4	COMPLETED	Can TNF-Alpha Incomplete Secondary Responders Attain a Safe and Efficacious Response Switching to Cimzia
NCT01295151	PHASE4	COMPLETED	SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug.
NCT01443364	PHASE4	COMPLETED	Open Label Study to Assess the Predictability of Early Response to Certolizumab Pegol in Patients With Rheumatoid Arthritis
NCT01491815	PHASE4	UNKNOWN	Active Conventional Therapy Compared to Three Different Biologic Treatments in Early Rheumatoid Arthritis With Subsequent Dose Reduction
NCT01696942	PHASE4	TERMINATED	Cimzia Versus Mesalamine for Crohn’s Recurrence
NCT02353780	PHASE4	TERMINATED	Mechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept
NCT02451748	PHASE4	COMPLETED	IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA
NCT02466581	PHASE4	UNKNOWN	Dose Reduction for Early Rheumatoid Arthritis Patients With Low Disease Activity
NCT02597829	PHASE4	UNKNOWN	Does Clinical Response Correlate With Serum Certolizumab Levels?
NCT03020992	PHASE4	COMPLETED	A Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis (AU) Flares in Axial Spondyloarthritis Subjects With a Documented History of AU
NCT03100253	PHASE4	TERMINATED	Rheumatoid Arthritis Treatment After First Anti-TNF INvestiGation
NCT04123795	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis
NCT00152386	PHASE3	COMPLETED	A Placebo Controlled Study to Assess Efficacy and Safety of Certolizumab Pegol in the Treatment of Rheumatoid Arthritis
NCT00152425	PHASE3	COMPLETED	Study to Test the Effect of CDP870 in the Treatment of Crohn’s Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo), Following 3 Doses of Active Drug (CDP870).
NCT00152490	PHASE3	COMPLETED	A Study to Test the Effect of CDP870 in the Treatment of Crohn’s Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo)
NCT00160524	PHASE3	COMPLETED	A follow-on Safety Study of CDP870 in Subjects With Crohn’s Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425]
NCT00160602	PHASE3	COMPLETED	A Study of Liquid Certolizumab Pegol as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis
NCT00160641	PHASE3	COMPLETED	A Study of the Safety and Effectiveness of Liquid Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis
NCT00160693	PHASE3	COMPLETED	Open Label Long-Term Safety Study of Certolizumab Pegol (CZP) for Patients With Rheumatoid Arthritis
NCT00160706	PHASE3	COMPLETED	A follow-on Safety Study in Subjects With Crohn’s Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn’s Disease
NCT00175877	PHASE3	COMPLETED	A Study of the Safety and Effectiveness of Lyophilized Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis
NCT00297648	PHASE3	COMPLETED	Mucosal Healing Study in Crohn’s Disease (CD)
NCT00307931	PHASE3	TERMINATED	Certolizumab Pegol for Treatment of Adult Greek Patients With Moderate to Severe Crohn’s Disease Who Failed Infliximab
NCT00308581	PHASE3	COMPLETED	Certolizumab in Crohn’s Disease Patients With Loss of Response or Intolerance to Infliximab
NCT00333788	PHASE3	COMPLETED	Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn’s Disease
NCT00349752	PHASE3	TERMINATED	Corticosteroid Sparing Effect of Certolizumab in Crohn’s Disease
NCT00354367	PHASE3	WITHDRAWN	Evaluate Efficacy of Certolizumab in Crohn’s Patients With Draining Fistulas
NCT00356408	PHASE3	COMPLETED	Examining the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Crohn’s Disease
NCT00358683	PHASE3	WITHDRAWN	A Trial Evaluating Safety of Chronic Therapy With Certolizumab Pegol in Crohn’s Disease
NCT00544154	PHASE3	COMPLETED	Efficacy and Safety of CDP870 and Methotrexate Compared to Methotrexate Alone in Subjects With Rheumatoid Arthritis
NCT00548834	PHASE3	COMPLETED	Efficacy and Safety of CDP870 Versus Placebo in the Treatment of the Signs and Symptoms of Rheumatoid Arthritis
NCT00552058	PHASE3	COMPLETED	Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn’s Disease
NCT00552344	PHASE3	COMPLETED	A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn’s Disease
NCT00674362	PHASE3	COMPLETED	Rheumatoid Arthritis (RA) Moderate to Low Disease Activity Study
NCT00753454	PHASE3	COMPLETED	Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)
NCT00791921	PHASE3	COMPLETED	Efficacy Confirmation Trial of CDP870 Without Coadministration of Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA)
NCT00791999	PHASE2/PHASE3	COMPLETED	Efficacy Confirmation Trial of CDP870 as add-on Medication to Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).